title: A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer.
abstract: BACKGROUND
  Mutations of the epidermal growth factor receptor (EGFR) gene at kinase domain have been reported in non-small-cell lung cancer (NSCLC). However, EGFR mutations status at C-terminal domain has not been reported in detail.
  
  
  METHODS
  We investigated the EGFR mutation and polymorphism statuses at C-terminal domain in 398 surgically treated NSCLC cases. Two hundred and sixty-eight adenocarcinoma cases were included. The presence or absence of EGFR mutation and polymorphism was analyzed by direct sequences.
  
  
  RESULTS
  A novel EGFR somatic mutation at exon 25 (G3034, D1012H) was found from 1 of 398 lung cancer patients. During sequencing of EGFR C-terminal domain in NSCLC, 194 EGFR polymorphism (C2982T) cases were identified at exon 25. The polymorphism statuses were not correlated with gender, smoking status (never smoker vs. smoker), pathological subtypes and EGFR mutations. The EGFR polymorphism ratio was significantly higher in younger NSCLC (< or =60, 56.8%) than in older NSCLC (>60, 45.6%, P = 0.0467). The EGFR polymorphism ratio was significantly higher in lymph node positive NSCLC (57.4%) than in lymph node negative NSCLC (44%, P = 0.0168). In 46 total gefitinib treated NSCLC patients, exon 25 polymorphism was not correlated with prognosis.
  
  
  CONCLUSIONS
  EGFR mutation at C-terminal in lung cancers seemed to be extremely rare, however, this D1012H mutation might be a role in EGFR function. EGFR polymorphism at exon 25 might be correlated with progression of NSCLC.
authors.affiliation: Department of Surgery II, Nagoya City University Medical School, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. hisasaki@med.nagoya-cu.ac.jp
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Sasaki
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Okuda
authors.forename: Minoru
authors.initials: M
authors.lastname: Takada
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kawahara
authors.forename: Naoto
authors.initials: N
authors.lastname: Kitahara
authors.forename: Akihide
authors.initials: A
authors.lastname: Matsumura
authors.forename: Keiji
authors.initials: K
authors.lastname: Iuchi
authors.forename: Tomoya
authors.initials: T
authors.lastname: Kawaguchi
authors.forename: Akihiko
authors.initials: A
authors.lastname: Kubo
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Endo
authors.forename: Osamu
authors.initials: O
authors.lastname: Kawano
authors.forename: Haruhiro
authors.initials: H
authors.lastname: Yukiue
authors.forename: Motoki
authors.initials: M
authors.lastname: Yano
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Fujii
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000556:secondary; D000368:Aged; D044466:Asian People / Q000235:genetics; D018196:Carcinoma, Adenosquamous / Q000235:genetics / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000556:secondary; D017931:DNA Primers; D066246:ErbB Receptors / Q000235:genetics*; D005091:Exons / Q000235:genetics*; D005260:Female; D006801:Humans; D008168:Lung / Q000378:metabolism / Q000473:pathology; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D012907:Smoking; D015996:Survival Rate
chemical_list: D017931:DNA Primers; D066246:ErbB Receptors